tiprankstipranks
Trending News
More News >
Cytokinetics (CYTK)
NASDAQ:CYTK
US Market

Cytokinetics (CYTK) Stock Forecast & Price Target

Compare
1,058 Followers
See the Price Targets and Ratings of:

CYTK Analyst Ratings

Strong Buy
18Ratings
Strong Buy
16 Buy
2 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Cytokinetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$76.07
▲(137.72%Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $76.07 with a high forecast of $120.00 and a low forecast of $41.00. The average price target represents a 137.72% change from the last price of $32.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","121":"$121","57.25":"$57.3","78.5":"$78.5","99.75":"$99.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,57.25,78.5,99.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.92,48.84923076923077,54.77846153846154,60.70769230769231,66.63692307692308,72.56615384615385,78.49538461538461,84.42461538461538,90.35384615384615,96.28307692307692,102.21230769230769,108.14153846153846,114.07076923076923,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.92,45.47,48.02,50.57,53.12,55.67,58.22,60.769999999999996,63.31999999999999,65.87,68.41999999999999,70.97,73.52,{"y":76.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.92,42.77230769230769,42.62461538461539,42.47692307692308,42.32923076923077,42.181538461538466,42.033846153846156,41.886153846153846,41.738461538461536,41.59076923076923,41.44307692307692,41.29538461538461,41.14769230769231,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.37,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.08,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$120.00Average Price Target$76.07Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CYTK
TipRanks AITipRanks
Not Ranked
TipRanks
$28
Sell
-12.50%
Downside
Reiterated
05/15/25
Cytokinetics faces significant financial and operational challenges impacting its overall stock score. The company struggles with negative profitability, high leverage, and negative cash flows. Technical indicators show bearish trends, and valuation metrics reflect financial strain. While the earnings call highlights some positive developments, the overall sentiment is mixed due to heightened expenses and approval delays. These factors contribute to a low overall stock score, suggesting caution for potential investors.
Barclays Analyst forecast on CYTK
Gena WangBarclays
Barclays
$53
Buy
65.63%
Upside
Reiterated
05/30/25
Barclays Remains a Buy on Cytokinetics (CYTK)
Mizuho Securities Analyst forecast on CYTK
Salim SyedMizuho Securities
Mizuho Securities
$103$84
Buy
162.50%
Upside
Reiterated
05/29/25
Mizuho Securities Remains a Buy on Cytokinetics (CYTK)
Stifel Nicolaus Analyst forecast on CYTK
James CondulisStifel Nicolaus
Stifel Nicolaus
$80$87
Buy
171.88%
Upside
Reiterated
05/26/25
Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)
H.C. Wainwright Analyst forecast on CYTK
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$120
Buy
275.00%
Upside
Reiterated
05/19/25
Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
Truist Financial Analyst forecast on CYTK
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (NASDAQ: YMAB), Claritev (NYSE: CTEV) and Cytokinetics (NASDAQ: CYTK)
Bank of America Securities Analyst forecast on CYTK
Jason ZemanskyBank of America Securities
Bank of America Securities
$45
Hold
40.63%
Upside
Reiterated
05/13/25
Cytokinetics' MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
J.P. Morgan Analyst forecast on CYTK
Tessa RomeroJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/13/25
Promising Phase 3 Results for Aficamten Boost Cytokinetics' Market Position in Hypertrophic Cardiomyopathy Treatment
Needham
$72
Buy
125.00%
Upside
Reiterated
05/13/25
Cytokinetics' Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
Morgan Stanley Analyst forecast on CYTK
Maxwell SkorMorgan Stanley
Morgan Stanley
$65
Buy
103.13%
Upside
Reiterated
05/13/25
Cytokinetics' Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
Leerink Partners Analyst forecast on CYTK
Roanna RuizLeerink Partners
Leerink Partners
Buy
Reiterated
05/13/25
Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy
Evercore ISI Analyst forecast on CYTK
Cory KasimovEvercore ISI
Evercore ISI
$65$60
Buy
87.50%
Upside
Reiterated
05/07/25
Cytokinetics (CYTK) PT Lowered to $60 at Evercore ISIEvercore ISI analyst Cory Kasimov lowered the price target on Cytokinetics (NASDAQ: CYTK) to $60.00 (from $65.00) while maintaining a Outperform rating.
Piper Sandler Analyst forecast on CYTK
Yasmeen RahimiPiper Sandler
Piper Sandler
$107
Buy
234.38%
Upside
Reiterated
05/07/25
Cytokinetics (CYTK) Gets a Buy from Piper Sandler
Citizens JMP Analyst forecast on CYTK
Jason ButlerCitizens JMP
Citizens JMP
$78
Buy
143.75%
Upside
Reiterated
05/07/25
Citizens JMP reiterates Market Outperform Rating on Cytokinetics (CYTK)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $78.00 price target on Cytokinetics (NASDAQ: CYTK).
Citi
$86$80
Buy
150.00%
Upside
Reiterated
05/06/25
Cytokinetics price target lowered to $80 from $86 at CitiCytokinetics price target lowered to $80 from $86 at Citi
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CYTK
TipRanks AITipRanks
Not Ranked
TipRanks
$28
Sell
-12.50%
Downside
Reiterated
05/15/25
Cytokinetics faces significant financial and operational challenges impacting its overall stock score. The company struggles with negative profitability, high leverage, and negative cash flows. Technical indicators show bearish trends, and valuation metrics reflect financial strain. While the earnings call highlights some positive developments, the overall sentiment is mixed due to heightened expenses and approval delays. These factors contribute to a low overall stock score, suggesting caution for potential investors.
Barclays Analyst forecast on CYTK
Gena WangBarclays
Barclays
$53
Buy
65.63%
Upside
Reiterated
05/30/25
Barclays Remains a Buy on Cytokinetics (CYTK)
Mizuho Securities Analyst forecast on CYTK
Salim SyedMizuho Securities
Mizuho Securities
$103$84
Buy
162.50%
Upside
Reiterated
05/29/25
Mizuho Securities Remains a Buy on Cytokinetics (CYTK)
Stifel Nicolaus Analyst forecast on CYTK
James CondulisStifel Nicolaus
Stifel Nicolaus
$80$87
Buy
171.88%
Upside
Reiterated
05/26/25
Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)
H.C. Wainwright Analyst forecast on CYTK
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$120
Buy
275.00%
Upside
Reiterated
05/19/25
Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
Truist Financial Analyst forecast on CYTK
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (NASDAQ: YMAB), Claritev (NYSE: CTEV) and Cytokinetics (NASDAQ: CYTK)
Bank of America Securities Analyst forecast on CYTK
Jason ZemanskyBank of America Securities
Bank of America Securities
$45
Hold
40.63%
Upside
Reiterated
05/13/25
Cytokinetics' MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
J.P. Morgan Analyst forecast on CYTK
Tessa RomeroJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/13/25
Promising Phase 3 Results for Aficamten Boost Cytokinetics' Market Position in Hypertrophic Cardiomyopathy Treatment
Needham
$72
Buy
125.00%
Upside
Reiterated
05/13/25
Cytokinetics' Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
Morgan Stanley Analyst forecast on CYTK
Maxwell SkorMorgan Stanley
Morgan Stanley
$65
Buy
103.13%
Upside
Reiterated
05/13/25
Cytokinetics' Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
Leerink Partners Analyst forecast on CYTK
Roanna RuizLeerink Partners
Leerink Partners
Buy
Reiterated
05/13/25
Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy
Evercore ISI Analyst forecast on CYTK
Cory KasimovEvercore ISI
Evercore ISI
$65$60
Buy
87.50%
Upside
Reiterated
05/07/25
Cytokinetics (CYTK) PT Lowered to $60 at Evercore ISIEvercore ISI analyst Cory Kasimov lowered the price target on Cytokinetics (NASDAQ: CYTK) to $60.00 (from $65.00) while maintaining a Outperform rating.
Piper Sandler Analyst forecast on CYTK
Yasmeen RahimiPiper Sandler
Piper Sandler
$107
Buy
234.38%
Upside
Reiterated
05/07/25
Cytokinetics (CYTK) Gets a Buy from Piper Sandler
Citizens JMP Analyst forecast on CYTK
Jason ButlerCitizens JMP
Citizens JMP
$78
Buy
143.75%
Upside
Reiterated
05/07/25
Citizens JMP reiterates Market Outperform Rating on Cytokinetics (CYTK)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $78.00 price target on Cytokinetics (NASDAQ: CYTK).
Citi
$86$80
Buy
150.00%
Upside
Reiterated
05/06/25
Cytokinetics price target lowered to $80 from $86 at CitiCytokinetics price target lowered to $80 from $86 at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

1 Month
xxx
Success Rate
10/15 ratings generated profit
67%
Average Return
+11.31%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +11.31% per trade.
3 Months
xxx
Success Rate
9/19 ratings generated profit
47%
Average Return
+10.17%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +10.17% per trade.
1 Year
Salim SyedMizuho Securities
Success Rate
31/50 ratings generated profit
62%
Average Return
+25.83%
reiterated a buy rating 7 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 62.00% of your transactions generating a profit, with an average return of +25.83% per trade.
2 Years
xxx
Success Rate
29/50 ratings generated profit
58%
Average Return
+21.83%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 58.00% of your transactions generating a profit, with an average return of +21.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
18
27
31
38
45
Buy
14
10
9
11
13
Hold
7
4
3
5
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
41
43
54
66
In the current month, CYTK has received 58 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 76.07.
Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.42 with a range of -$1.60 to -$1.24. The previous quarter’s EPS was -$1.36. CYTK beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.
Next quarter’s earnings estimate for CYTK is -$1.42 with a range of -$1.60 to -$1.24. The previous quarter’s EPS was -$1.36. CYTK beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $2.01M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $1.58M. CYTK beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.
Next quarter’s sales forecast for CYTK is $2.01M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $1.58M. CYTK beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CYTK has Outperformed its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 76.07.
    What is CYTK’s upside potential, based on the analysts’ average price target?
    Cytokinetics has 137.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CYTK a Buy, Sell or Hold?
          Cytokinetics has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Cytokinetics’s price target?
            The average price target for Cytokinetics is 76.07. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $120.00 ,the lowest forecast is $41.00. The average price target represents 137.72% Increase from the current price of $32.
              What do analysts say about Cytokinetics?
              Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of CYTK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis